Literature DB >> 32308482

Ultrasound-Mediated Co-Delivery of miR-34a and sPD-1 Complexed with Microbubbles for Synergistic Cancer Therapy.

Yu-E Qin1, Wen-Fan Tang1, Yun Xu1, Fu-Rong Wan1, Ai-Hua Chen1.   

Abstract

BACKGROUND: miR-34a was downregulated and PD-L1 was upregulated in cervical cancer; however, the treatment of cervical cancer lacks precision and targeting. This study explored the ultrasound-mediated co-delivery of miR-34a and sPD-1 complexes with microbubbles for synergistic cancer therapy.
METHODS: Cationic lipid microbubbles (CLMBs) were prepared by membrane hydration and mechanical oscillation. U14 subcutaneous xenograft mice were injected with CLMBs-loaded sPD-1 and miR-34a combined with ultrasound targeted destruction, and tumor volume and tumor weight of mice were measured. TUNEL apoptosis test and the mRNA expression of apoptosis-related gene Bcl-2 and Bax were analyzed by qRT-PCR. Antitumor immune-related cytokines IFN-γ were investigated by qRT-PCR, LDH Cytotoxicity Assay Kit were performed to test cytotoxic T lymphocytes (CTL).
RESULTS: CLMBs were successfully prepared and the plasmid bound to its surface. The tumor volume and weight were specifically decreased by ultrasound-mediated co-delivery of miR-34a and sPD-1 complexes with microbubbles, apoptosis was induced and the apoptosis suppressor gene Bcl-2 was downregulated and proapoptotic gene Bax were upregulated. qRT-PCR analysis revealed that antitumor immunity-related IFN-γ was strongly upregulated in mice, which were treated with CLMBs-loaded sPD-1 and miR-34a combined with ultrasound targeted destruction, and the percentage of CTL was increased.
CONCLUSION: These findings from the study demonstrated that CLMBs could deliver miR-34a and sPD-1, combined with ultrasound targeted destruction, could suppress the tumor tissue growing, induce apoptosis and enhance antitumor immunity in U14 subcutaneous xenograft mice.
© 2020 Qin et al.

Entities:  

Keywords:  cancer therapy; cervical cancer; miR-34a; microbubbles; sPD-1; ultrasound

Year:  2020        PMID: 32308482      PMCID: PMC7148163          DOI: 10.2147/CMAR.S238643

Source DB:  PubMed          Journal:  Cancer Manag Res        ISSN: 1179-1322            Impact factor:   3.989


  44 in total

1.  A novel therapeutic strategy using ultrasound mediated microbubbles destruction to treat colon cancer in a mouse model.

Authors:  Pintong Huang; Xiangdong You; Minqiang Pan; Shiyan Li; Ying Zhang; Yingzhen Zhao; Minghui Wang; Yurong Hong; Zhaoxia Pu; Lirong Chen; Guangen Yang; Youmin Guo
Journal:  Cancer Lett       Date:  2013-02-13       Impact factor: 8.679

2.  Nanobubble-Affibody: Novel ultrasound contrast agents for targeted molecular ultrasound imaging of tumor.

Authors:  Hengli Yang; Wenbin Cai; Lei Xu; Xiuhua Lv; Youbei Qiao; Pan Li; Hong Wu; Yilin Yang; Li Zhang; Yunyou Duan
Journal:  Biomaterials       Date:  2014-10-30       Impact factor: 12.479

3.  Synergistic anti-tumor effect of paclitaxel and miR-34a combined with ultrasound microbubbles on cervical cancer in vivo and in vitro.

Authors:  J Yu; Y Zhao; C Liu; B Hu; M Zhao; Y Ma; J Jiang
Journal:  Clin Transl Oncol       Date:  2019-05-15       Impact factor: 3.405

4.  Folate-conjugated gene-carrying microbubbles with focused ultrasound for concurrent blood-brain barrier opening and local gene delivery.

Authors:  Ching-Hsiang Fan; En-Ling Chang; Chien-Yu Ting; Yu-Chun Lin; En-Chi Liao; Chiung-Yin Huang; Yuan-Chih Chang; Hong-Lin Chan; Kuo-Chen Wei; Chih-Kuang Yeh
Journal:  Biomaterials       Date:  2016-08-12       Impact factor: 12.479

5.  B cell lymphoma 2 (Bcl-2) residues essential for Bcl-2's apoptosis-inducing interaction with Nur77/Nor-1 orphan steroid receptors.

Authors:  Karl L Banta; Xinyue Wang; Phani Das; Astar Winoto
Journal:  J Biol Chem       Date:  2018-02-02       Impact factor: 5.157

6.  Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer.

Authors:  Jyoti Mayadev; Dmitriy Zamarin; Wei Deng; Heather Lankes; Roisin O'Cearbhaill; Carol A Aghajanian; Russell Schilder
Journal:  Int J Gynecol Cancer       Date:  2019-12-22       Impact factor: 3.437

7.  Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas.

Authors:  Eleni Anastasiadou; Dina Stroopinsky; Stella Alimperti; Alan L Jiao; Athalia R Pyzer; Claudia Cippitelli; Giuseppina Pepe; Martina Severa; Jacalyn Rosenblatt; Marilena P Etna; Simone Rieger; Bettina Kempkes; Eliana M Coccia; Shannan J Ho Sui; Christopher S Chen; Stefania Uccini; David Avigan; Alberto Faggioni; Pankaj Trivedi; Frank J Slack
Journal:  Leukemia       Date:  2018-06-26       Impact factor: 11.528

8.  Ultrasound-mediated delivery of siESE complexed with microbubbles attenuates HER2+/- cell line proliferation and tumor growth in rodent models of breast cancer.

Authors:  Kang-Ho Song; Tammy Trudeau; Adwitiya Kar; Mark A Borden; Arthur Gutierrez-Hartmann
Journal:  Nanotheranostics       Date:  2019-05-13

Review 9.  Roles of the immune system in cancer: from tumor initiation to metastatic progression.

Authors:  Hugo Gonzalez; Catharina Hagerling; Zena Werb
Journal:  Genes Dev       Date:  2018-10-01       Impact factor: 11.361

10.  'DURVIT': a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment.

Authors:  J Rotman; C H Mom; E S Jordanova; T D de Gruijl; G G Kenter
Journal:  BMC Cancer       Date:  2018-09-12       Impact factor: 4.430

View more
  5 in total

Review 1.  Therapeutic Targeting of MicroRNAs in the Tumor Microenvironment.

Authors:  Rebecca Raue; Ann-Christin Frank; Shahzad Nawaz Syed; Bernhard Brüne
Journal:  Int J Mol Sci       Date:  2021-02-23       Impact factor: 5.923

Review 2.  Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy.

Authors:  Muhammad Khan; Zhihong Zhao; Sumbal Arooj; Yuxiang Fu; Guixiang Liao
Journal:  Front Immunol       Date:  2020-11-19       Impact factor: 7.561

3.  Nanobubbles Containing sPD-1 and Ce6 Mediate Combination Immunotherapy and Suppress Hepatocellular Carcinoma in Mice.

Authors:  Yandi Tan; Shiqi Yang; Yao Ma; Jinlin Li; Qian Xie; Chaoqi Liu; Yun Zhao
Journal:  Int J Nanomedicine       Date:  2021-05-10

Review 4.  Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer.

Authors:  Mengke Niu; Yiming Liu; Ming Yi; Dechao Jiao; Kongming Wu
Journal:  Front Immunol       Date:  2022-03-21       Impact factor: 7.561

Review 5.  Synergies between therapeutic ultrasound, gene therapy and immunotherapy in cancer treatment.

Authors:  Nisi Zhang; James Wang; Josquin Foiret; Zhifei Dai; Katherine W Ferrara
Journal:  Adv Drug Deliv Rev       Date:  2021-07-30       Impact factor: 15.470

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.